DailyFinance  8 hrs ago  Comment 
Filed under: News, Drugs & Medicine Dec 6 (Reuters) - Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with...
GenEng News  8 hrs ago  Comment 
Data from a Phase III study evaluating Novartis’ selective anaplastic lymphoma kinase (ALK) gene inhibitor, Zykadia® (ceritinib), showed that first-line treatment with the drug resulted in a 45% reduction in the risk of disease progression in...
Reuters  9 hrs ago  Comment 
Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth.
newratings.com  Dec 6  Comment 
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC Novartis International AG / Novartis announces Zykadia® first-line study results showing 16.6 month...
The Economic Times  Dec 6  Comment 
Lupin has 139 product filings pending approval with the USFDA. Cumulative filings with the USFDA now stand at 341 with the company having received approvals for 202 products.
newratings.com  Dec 6  Comment 
BASEL (dpa-AFX) - Novartis announced the new data from the Tasigna or nilotinib ENESTop Treatment-free Remission or TFR study, which demonstrate that TFR rates are consistent among Philadelphia chromosome-positive or Ph+ chronic myeloid leukemia...
newratings.com  Dec 5  Comment 
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec® Novartis International AG / Novartis data shows Treatment-free Remission rates are consistently above 50%...
newratings.com  Dec 5  Comment 
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work Novartis International AG / Novartis survey uncovers real-world burden of myeloproliferative neoplasms...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki